Biomarin Pharmaceutical (BMRN) Change in Cash (2009 - 2026)

Biomarin Pharmaceutical has disclosed Change in Cash across 18 years of filings, most recently posting $1.8 billion for Q1 2026.

• Quarterly Change in Cash rose 1561.7% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 570.51% YoY) and the FY2025 annual result came in at $368.8 million, up 96.49% from the prior year.
• Change in Cash rose to $1.8 billion in Q1 2026, from $61.6 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.8 billion in Q1 2026 and troughed at -$296.7 million in Q3 2024.
• A 5-year average of $146.2 million and a median of $61.6 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash tumbled 895.29% — and 2026, when it surged 1561.7%.
• Tracing BMRN's Change in Cash over 5 years: stood at -$37.0 million in 2022, then gained by 18.11% to -$30.3 million in 2023, then soared by 982.87% to $267.4 million in 2024, then slumped by 76.97% to $61.6 million in 2025, then soared by 2759.72% to $1.8 billion in 2026.
• Business Quant data shows BMRN's Change in Cash at $1.8 billion in Q1 2026, $61.6 million in Q4 2025, and $36.3 million in Q3 2025.